CAREFULLY FORMULATED WITH POLYMERIC MESH TECHNOLOGY1

Polymeric mesh allows even distribution of active ingredients2,3

Formulated with the following inactive ingredients2,3:

  • Purified water (solvent)
  • Carbomer homopolymer (gelling agent)
  • Propylene glycol (humectant)
  • Potassium hydroxide (alkalizing agent)
formula one formula one formula one formula one
formula one
Substraction

CABTREO is dispensed from a measured-dosing pump that utilizes patented polymeric mesh technology to suspend active ingredients in place for even distribution across the skin1-3

ONE SCRIPT. ONE PUMP.
ONE APPLICATION A DAY.1

With one application a day, CABTREO can become a part of your patient’s daily routine.1

Actor portrayal of an acne patient who could be treated with CABTREO. Not an actual patient. Actor portrayal of an acne patient who could be treated with CABTREO. Not an actual patient.

Not an actual patient.

Learn about the Moa of cabtreo icon

Learn about the Moa of cabtreo icon

See More

Important Safety Information AND INDICATION

CONTRAINDICATIONS

CABTREO is contraindicated in patients with:

  • known hypersensitivity to clindamycin, adapalene, benzoyl peroxide, any components of the formulation, or lincomycin.
  • history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.
See Less

Important Safety Information AND INDICATION

CONTRAINDICATIONS

CABTREO is contraindicated in patients with:

  • known hypersensitivity to clindamycin, adapalene, benzoyl peroxide, any components of the formulation, or lincomycin.
  • history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, angioedema, and urticaria, have been reported. If a serious hypersensitivity reaction occurs, discontinue CABTREO immediately and initiate appropriate therapy.

Colitis: Clindamycin can cause severe colitis, which may result in death. Discontinue CABTREO if diarrhea occurs.

Photosensitivity: CABTREO may increase sensitivity to ultraviolet light. Avoid or minimize exposure to sunlight and sunlamps. Wear sunscreen and protective clothing when sun exposure cannot be avoided.

Skin Irritation and Allergic Contact Dermatitis: Stinging/burning/pain, erythema, dryness, irritation, exfoliation, and dermatitis may occur with use of CABTREO and may necessitate discontinuation. Weather extremes, such as wind or cold, may be irritating to patients under treatment with CABTREO. Depending upon severity, patients can use a moisturizer, reduce frequency of application, or discontinue use. Avoid applying CABTREO to areas of broken, eczematous, or sunburned skin, and concomitant use with other potentially irritating topical products. Avoid use of “waxing” as a depilatory method on skin treated with CABTREO.

Use of CABTREO with concomitant topical acne therapy has not been evaluated.

ADVERSE REACTIONS

The most common adverse reactions (occurring in >1% of the CABTREO group and greater than the vehicle group) were application site reactions, pain, erythema, dryness, irritation, exfoliation, and dermatitis.

DRUG INTERACTIONS

Use CABTREO with caution in patients receiving neuromuscular blocking agents.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Indication

CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1% is indicated for the topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older.

Please click here for full Prescribing Information.

References: 1. CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1% [prescribing information]. Bridgewater, NJ. Bausch Health US, LLC. 2. Ortho Dermatologics. Data on file. 3. Stein Gold L, Baldwin H, Kircik LH, et al. Efficacy and safety of a fixed‑dose clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate‑to‑severe acne: a randomized phase II study of the first triple‑combination drug. Am J Clin Dermatol. 2022;23(1):93-104.